Company Of The Day: Pfizer
What?
Pfizer (NYSE:PFE) posted better than expected Q4 2021 earnings, with adjusted EPS coming in at $1.08, up from about $0.43 in Q4 2020. However, revenue growth, which came in at 104% year-over-year, missed estimates.
Why?
Relevant Articles
- After A 30% Fall In A Year Is Pfizer Stock A Better Pick Over Merck?
- Should You Pick Pfizer Stock At $30 After A 30% Fall In A Year?
- Should You Pick Pfizer Stock At $30?
- Down 25% In A Year Will Pfizer Stock Rebound To Its Pre-Inflation Shock Level?
- Will Pfizer Stock See Higher Levels Post Q1 Earnings?
- Is Pfizer Stock Undervalued At $40?
Growth was driven primarily by Pfizer’s Covid-19 vaccine. Excluding the vaccine and the new Covid-19 treatment, Pfizer’s revenues actually declined by 2%.
So What?
Pfizer stock declined by about 3% in Tuesday’s trading.
See Our Complete Analysis For Pfizer
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.
| Returns | Feb 2022 MTD [1] |
2022 YTD [1] |
2017-22 Total [2] |
| PFE Return | -2% | -12% | 59% |
| S&P 500 Return | 0% | -5% | 102% |
| Trefis MS Portfolio Return | 0% | -9% | 258% |
[1] Month-to-date and year-to-date as of 2/9/2022
[2] Cumulative total returns since the end of 2016
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates